Marinus Pharmaceuticals reported $168.25M in Cash and Equivalent for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Acadia Pharmaceuticals ACAD:US USD 436.58M 296.75M
ALKERMES ALKS:US USD 263.96M 9.31M
Amgen AMGN:US USD 9.5B 4.3B
Aptinyx Inc APTX:US USD 66.58M 18.68M
Biogen BIIB:US USD 3.68B 1.03B
Eisai 4523:JP JPY 264.53B 23.29B
Enanta Pharmaceuticals ENTA:US USD 43.99M 15.63M
Esperion Therapeutics ESPR:US USD 159.4M 36.46M
Gilead Sciences GILD:US USD 6.94B 2.2B
Intercept Pharmaceuticals ICPT:US USD 113.2M 55.18M
Intra Cellular Therapies ITCI:US USD 135.36M 58.12M
Marinus Pharmaceuticals MRNS:US USD 168.25M 75.92M
Minerva Neurosciences NERV:US USD 40.22M 9.53M
Neurocrine Biosciences NBIX:US USD 212.2M 48.9M
Ptc Therapeutics PTCT:US USD 104.42M 53.73M
Regeneron Pharmaceuticals REGN:US USD 3.49B 96.2M
Sarepta Therapeutics SRPT:US USD 1.04B 170.06M
Supernus Pharmaceuticals SUPN:US USD 111.49M 61.94M
Vertex Pharmaceuticals VRTX:US USD 9.17B 469.3M
YTE INCY:US USD 2.69B 255.24M